Blánquez-Martínez David, Díaz-Villamarín Xando, Antúnez-Rodríguez Alba, Pozo-Agundo Ana, Muñoz-Ávila José Ignacio, Martínez-González Luis Javier, Dávila-Fajardo Cristina Lucía
Pharmacy Department, Hospital Universitario de Ceuta, 51003 Ceuta, Spain.
Pharmacy Department, Hospital Universitario Clínico San Cecilio, 18016 Granada, Spain.
Pharmaceutics. 2021 Nov 20;13(11):1973. doi: 10.3390/pharmaceutics13111973.
High myopia is an ophthalmic pathology that affects half of the young adults in the United States and Europe and it is predicted that a third of the world's population could be nearsighted at the end of this decade. It is characterized by at least 6 diopters or axial length > 26 mm and, choroidal neovascularization (CNV) in 5 to 11% of cases. Ranibizumab is a recombinant humanized monoclonal antibody fragment. It is an anti-vascular endothelial growth factor (anti-VEGF) drug used in the treatment of CNV. Many genetic polymorphisms have been associated with interindividual differences in the response to ranibizumab, but these associations were not yet assessed among patients with high myopia and CNV. We performed a retrospective study assessing the association of genetic polymorphisms with response to ranibizumab in patients with CNV secondary to high myopia (mCNV). We included genetic polymorphisms previously associated with the response to drugs used in CNV patients (bevacizumab, ranibizumab, aflibercept, and photodynamic therapy (PDT)). We also included genetic variants in the gene. Based on our results, (rs10490924) and (rs1061170) are associated with response to ranibizumab in high myopia patients; and, included genetic polymorphisms are not associated with ranibizumab response in our population but might be related to a higher risk of CNV.
高度近视是一种眼科疾病，影响着美国和欧洲一半的年轻人，预计到本十年末全球三分之一的人口可能会近视。其特征是至少6屈光度或眼轴长度>26毫米，5%至11%的病例会出现脉络膜新生血管（CNV）。雷珠单抗是一种重组人源化单克隆抗体片段。它是一种用于治疗CNV的抗血管内皮生长因子（抗VEGF）药物。许多基因多态性与雷珠单抗治疗反应的个体差异有关，但在高度近视合并CNV的患者中尚未评估这些关联。我们进行了一项回顾性研究，评估高度近视继发CNV（mCNV）患者基因多态性与雷珠单抗治疗反应的关联。我们纳入了先前与CNV患者使用的药物（贝伐单抗、雷珠单抗、阿柏西普和光动力疗法（PDT））治疗反应相关的基因多态性。我们还纳入了该基因中的遗传变异。根据我们的结果，（rs10490924）和（rs1061170）与高度近视患者对雷珠单抗的反应相关；并且，纳入的基因多态性在我们的人群中与雷珠单抗反应无关，但可能与CNV的较高风险有关。
